Novel immunotherapeutic approaches to glioma

Current Opinion in Molecular Therapeutics

Volumn 8, Issue 1, 2006, Pages 46-51

  Yamanaka, Ryuya ^a  

^a NIIGATA UNIVERSITY   (Japan)

Author keywords

Dendritic cells; Glioma; Immunotherapy; Peptide vaccination

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER TESTIS ANTIGEN; CANCER VACCINE; DENDRITIC CELL VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GLYCOPROTEIN GP 100; MELANOMA ANTIGEN; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 3; MONOPHENOL MONOOXYGENASE; PICIBANIL; PROTEIN P97; RECOMBINANT INTERLEUKIN 12; STROMAL CELL DERIVED FACTOR 1; TENASCIN; TUMOR ANTIGEN; TYROSINASE RELATED PROTEIN 1; TYROSINASE RELATED PROTEIN 2;

ABSENCE OF SIDE EFFECTS; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; BRAIN RADIATION; BRAIN SURGERY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EDEMA; GLIOBLASTOMA; GLIOMA; HUMAN; IMMUNOSTIMULATION; INJECTION SITE SWELLING; NONHUMAN; PROTECTION; REVIEW; SKIN REDNESS; SYSTEMIC THERAPY; TREATMENT OUTCOME; TUMOR IMMUNITY;

ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS; DENDRITIC CELLS; GLIOMA; HUMANS; IMMUNOTHERAPY;

EID: 32544460228     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Stewart LA: Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomized trials. Lancet (2002) 359(9311):1011-1018.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 352(10):987-996.
3. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC: Vaccination with irradiated tumor cells engineered to secrete marine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA (1993) 90(8):3539-3543.
4. Medawar PB: Immunity to homologous grafted skin: III. The fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol (1948) 29:58-69.
5. Satoh J, Lee YB, Kim SU: T-cell costimulatory molecules B7-1 (CD80) and B7-2 (CD86) are expressed in human microglia but not in astrocytes in culture. Brain Res (1995) 704(1):92-96.
6. Constam DB, Philipp J, Malipiero W, ten Dijke P, Schachner M, Fontana A: Differential expression of transforming growth factor-β1, -β2, and -β3 by glioblastoma cells, astrocytes, and microglia. J Immunol (1992) 148(5):1404-1410.
7. Gabrilovich DI, Ishida T, Nadaf S, Ohm JE, Carbons DP: Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res (1998) 5(10):2963-2970.
8. Chen Q, Daniel V, Maher DW, Hersey P: Production of IL-10 by melanoma cells: Examination of its role in immunosuppression mediated by melanoma. Int J Cancer (1994) 56(5):755-760.
9. Sampson JH, Archer GE, Ashley DM, Fuchs HE, Hale LP, Dranoff G, Bigner DD: Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. Proc Natl Acad Sci USA (1996) 93(19):10399-10404.
10. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, Deleo AB, Lotze MT: Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med (1995) 1(12):1297-1302.
11. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD Jr: Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med (1996) 183(1):283-287.
12. Paglia P, Chiodoni C, Rodolfo M, Colombo MP: Marine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med (1996) 183(1):317-322.
13. Porgador A, Gilboa E: Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J Exp Med (1995) 182(1):255-260.
14. Rosenberg SA: A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity (1999) 10(3):281-287.
15. Boczkowski D, Nair SK, Snyder D, Gilboa E: Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med (1996) 184(2):465-472.
16. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidl B, Engleman EG, Levy R: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med (1996) 2(1):52-58.
17. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med (1998) 4(3):328-332.
18. Tjoa BA, Simmons SJ, Bowes VA, Ragde H, Rogers M, Elgamal A, Kenny GM, Cobb OE, Ireton RC, Troychak MJ, Saigaller ML et al: Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate (1998) 36(1):39-44.
19. Kugler A, Stuhler G, Walden P, Zoller G, Zobywaiski A, Brossart P, Trefzer U, Ullrich S, Muller CA, Becker V, Gross AJ et al: Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med (2000) 6(3):332-336.
20. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 254(5038):1643-1647.
21. Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR, Appella E, Rosenberg SA: Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med (1994) 180(1):347-352.
22. Robbins PF, El-Gamil M, Li YF, Kawakami Y, Loftus D, Appella E, Rosenberg SA: A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med (1996) 183(3):1185-1192.
23. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR et al: Immunologic and therapeutic evaluation of a synthetic peptide vacine for the treatment of patients with metastatic melanoma. Nat Med (1998) 4(3):321-327.
24. Gaugler B, Van den Eynde B, van der Bruggen P, Romero P, Gaforio JJ, De Plaen E, Lethe B, Brasseur F, Boon T: Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med (1994) 179(3):921-930.
25. Song YH, Connor E, Li Y, Zorovich B, Balducci P, Maclaren N: The role of tyrosinase in autoimmune vitiligo. Lancet (1994) 344(8929):1049-1052.
26. Barth A, Hoon DS, Foshag LJ, Nizze JA, Famatiga E, Okun E, Morton DL: Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response. Cancer Res (1994) 54(13):3342-3345.
27. Lailier TE: Cell lineage and cell migration in the neural crest. Ann NY Acad Sci (1991) 615:158-171.
28. Kuramoto T: Detection of MAGE-1 tumor antigen in brain tumor. Kurume Med J (1997) 44(1):43-51.
29. Sasaki M, Nakahira K, Kawano Y, Katakura H, Yoshimine T, Shimizu K, Kim SU, Ikenaka K: MAGE-E1, a new member of the melanoma-associated antigen gene family and its expression in human glioma. Cancer Res (2001) 61(12):4809-4814.
30. Kurpad SN, Zhao XG, Wikstrand CJ, Batra SK, McLendon RE, Bigner DD: Tumor antigens in astrocytic gliomas. Glia (1995) 15(3):244-256.
31. Sahin U, Koslowski M, Tureci O, Eberle T, Zwick C, Romeike B, Moringlane JR, Schwechheimer K, Feiden W, Pfreundschuh M: Expression of cancer testis genes in human brain tumors. Clin Cancer Res (2000) 6(10):3916-3922.
32. Scarcella DL, Chow CW, Gonzales MF, Economou C, Brasseur F, Ashley DM: Expression of MAGE and GAGE in high-grade brain tumors: A potential target for specific immunotherapy and diagnostic markers. Clin Cancer Res (1999) 5(2):335-341.
33. Ueda R, Iizuka Y, Yoshida K, Kawase T, Kawakami Y, Toda M: Identification of a human glioma antigen, SOX6, recognized by patients' sera. Oncogene (2004) 23(7):1420-1427.
34. Imaizumi T, Kuramoto T, Matsunaga K, Shichijo S, Yutani S, Shigemori M, Oizumi K, Itoh K: Expression of the tumor-rejection antigen SART1 in brain tumors. Int J Cancer (1999) 83(6):760-764.
35. Murayama K, Kobayashi T, Imaizumi T, Matsunaga K, Kuramoto T, Shigemori M, Shichijo S, Itoh K: Expression of the SART3 tumor-rejection antigen in brain tumors and induction of cytotoxic T lymphocytes by its peptides. J Immunother (2000) 23(5):511-518.
36. Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, Lee PK, Yong WH, Incardona F, Thompson RC, Riedinger MS, Zhang W et al: Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res (2001) 61(3):842-847.
37. Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ: Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res (2004) 64(14):4973-4979.
38. Kikuchi T, Akasaki Y, Irie M, Homma S, Abe T, Ohno T: Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother (2001) 50(7):337-344.
39. Kikuchi T, Akasaki Y, Abe T, Fukuda T, Saotome H, Ryan JL, Kufe DW, Ohno T: Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother (2004) 27(6):452-459.
40. Rutkowski S, De Vleeschouwer S, Kaempgen E, Wolff JE, Kuhl J, Demaerel P, Warmuth-Metz M, Flamen P, Van Calenbergh F, Plets C, Sorensen N et al: Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br J Cancer (2004) 91(9):1656-1662.
41. Yamanaka R, Abe T, Yajima N, Tsuchiya N, Homma J, Kobayashi T, Narita M, Takahashi M, Tanaka R: Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: Results of a clinical phase I/II trial. Br J Cancer (2003) 89(7):1172-1179.
42. Yamanaka R, Homma J, Yajima N, Tsuchiya N, Sano M, Kobayashi T, Yoshida S, Abe T, Narita M, Tahahashi M, Tanaka R: Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: Results of a clinical phase I/II trial. Clin Cancer Res (2005) 11(11):4160-4167.
43. Schneider T, Gerhards R, Kirches E, Firsching R: Preliminary results of active specific immunization with modified tumor cell vaccine in glioblastoma multiforme. J Neurooncol (2001) 53(1):39-46.
44. Kruse CA, Cepeda L, Owens B, Johnson SD, Stears J, Lillehei KO: Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2. Cancer Immunol Immunother (1997) 45(2):77-87.
45. Townsend AR, Gotch FM, Davey J: Cytotoxic T cells recognize fragments of the influenza nucleoprotein. Cell (1985) 42(2):457-467.
46. Rosenberg SA, Yang JC, Restifo NP: Cancer immunotherapy: Moving beyond current vaccines. Nat Med (2004) 10(9):909-915.
47. Miyagi Y, Imai N, Sasatomi T, Yamada A, Mine T, Katagiri K, Nakagawa M, Muto A, Okouchi S, Isomoto H, Shirouzu K et al: Induction of cellular immune response to tumor cells and peptides in colorectal cancer patients by vaccination of SART3 peptides. Clin Cancer Res (2001) 7(12):3950-3962.
48. Tsuda N, Mochizuki K, Harada M, Sukehiro A, Kawano K, Yamada A, Ushijima K, Sugiyama T, Nishida T, Yamana H, Itoh K, Kamura T: Vaccination with predesignated or evidence-based peptides for patients with recurrent gynecologic cancers. J Immunother (2004) 27(1):60-72.
49. Noguchi M, Itoh K, Suekane S, Morinaga A, Sukehiro A, Suetsugu N, Katagiri K, Yamada A, Noda S: Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer. Prostate (2004) 60(1):32-45.
50. Mine T, Sato Y, Noguchi M, Sasatomi T, Gouhara R, Tsuda N, Tanaka S, Shomura H, Katagiri K, Rikimaru T, Shichijo S et al: Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing peptide-specific cellular responses. Clin Cancer Res (2004) 10(3):929-937.
51. Yajima N, Yamanaka R, Mine T, Tsuchiya N, Homma J, Sano M, Kuramoto T, Obata Y, Komatsu N, Arima Y, Yamada A et al: Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin Cancer Res (2005) 11(16):5900-5911.
52. Grabbe S, Kampgen E, Schuler G: Dendritic cells: Multi-lineal and multi-functional. Immunol Today (2000) 21(9):431-433.
53. Steiner HH, Bonsanto MM, Beckhove P, Brysch M, Geletneky K, Ahmadi R, Schuele-Freyer R, Kremer P, Ranaie G, Matejic D, Bauer H et al: Antitumor vaccination of patients with glioblastoma multiforme: A pilot study to assess feasibility, safety, and clinical benefit. J Clin Oncol (2004) 22(21):4272-4281.